Hexagon Bio, Inc.

Hexagon Bio, Inc. , founded in 2016, specializes in developing innovative medicines, particularly next-generation antibody drug conjugates (ADCs) for cancer treatment, utilizing advanced computational and chemical technologies. Based in Menlo Park, California, Hexagon Bio, Inc. focuses on pioneering therapies primarily in oncology.

Founded by Brian Naughton, Colin Harvey, and Maureen Hillenmeyer, the company has raised USD 67. 32 mn in SERIES B funding as of September 30, 2022, including investments from CPP Investment Board and existing investors such as 8VC and Two Sigma Ventures. To date, the company has completed three funding deals with a current valuation of USD 297. 60 mn.

Hexagon Bio, Inc. focuses on the discovery and development of innovative medicines, particularly next-generation antibody drug conjugates (ADCs) aimed at treating cancer. The company's core product offerings leverage advanced computational and chemical technologies to identify ADC payloads that possess novel mechanisms distinct from existing therapies. This strategic approach targets patient populations with significant unmet medical needs, enhancing treatment options for various cancer types.

Hexagon Bio’s services cater to biopharmaceutical companies and healthcare providers globally, emphasizing markets across North America, Europe, and Asia. By harnessing the power of nature’s genetic material, Hexagon Bio aims to transform genomic insights into actionable therapeutic solutions for patients in need. Hexagon Bio generates revenue through partnerships and collaborations with biopharmaceutical companies, leveraging their unique product offerings in the ADC space. These transactions typically involve collaborative research and development agreements, where Hexagon provides its advanced payloads to partners for further clinical development in specific oncology applications.

Revenue streams may include milestone payments upon achieving developmental benchmarks and royalties on future sales of products derived from these collaborations. While specific pricing plans for individual products or services are not disclosed, the firm's structure is strategically designed to align with the interests of its partners, ensuring shared goals in addressing complex cancer treatment challenges. In September 2022, Hexagon Bio, Inc. raised USD 67.

32 mn in SERIES B funding to expand its novel computational discovery platform and advance microbial genome-derived small molecules. The company plans to enhance its product pipeline and explore new therapeutic avenues, targeting additional markets in North America, Europe, and parts of Asia by the end of 2024.